FDA approves Medtronic's GEM III ICD (implantable cardioverter defibrillator):
This article was originally published in Clinica
The US FDA has approved for sale Medtronic's GEM III AT implantable cardioverter defibrillator (ICD) for managing patients with ventricular tachyarrhythmia with or without atrial fibrillation. The Minneapolis, Minnesota company said the device offers a number of enhancements compared to its GEM II and Jewel AF ICDs. It includes the InCheck AT Patient Assistant, which provides: ambulatory symptom marking and heart rhythm status to the patient; an improved version of its PR Logic dual chamber detection algorithm, which increases its ability to distinguish between lethal and nonlethal arrhythmias; and increased energy output.
You may also be interested in...
Liquid biopsy start-up Grail Inc. announced that a study of almost 6,700 participants found that its blood test could detect more than 50 types of cancer with a low false-positive rate. See what Minetta Liu, study co-lead author and a Mayo Clinic professor of oncology, had to say about the research.
Sanofi’s next-generation meningococcal vaccine, broader use of Bristol-Myers Squibb’s Reblozyl move toward approval; United Therapeutics foreshadows Trevyent regulatory difficulties.
Biopharma is working on a reputation renaissance as the public looks to industry for treatments and vaccines for the COVID-19 epidemic and drug pricing concerns take a back seat.